#United States #Class Action #San Francisco #Securities Fraud #Hims & Hers

Legal Trouble for Hims & Hers Health Inc.

Hims & Hers Health, Inc., trading under ticker symbol $HIMS, is currently embroiled in a significant legal battle. This class action lawsuit, initiated following allegations from the Federal Trade Commission (FTC), raises grave concerns over the company's business practices. Investors are now grappling with the fallout from a series of alarming claims against the company's executives.

Background of the Lawsuit

The FTC's federal complaint alleges that Hims engaged in serious misconduct by failing to uphold promised standards of privacy and data security. Despite their marketing campaigns insisting they protect sensitive health information, the complaint outlines that Hims shared user data with external advertising companies, including major platforms such as Meta and Snap, violating consumer trust and regulatory expectations.

The lawsuit points out several issues related to consumer rights, emphasizing how Hims charged users for prescriptions almost immediately after they completed their intake forms, contrary to their assertions that a consultation with a medical provider would precede such charges. This misrepresentation, according to the class action claims, highlights potential violations of the Restore Online Shoppers' Confidence Act (ROSCA) due to the way subscription models were presented to consumers.

Details of Alleged Misconduct

Hims has found itself criticized for:

• - Deceptive Health Data Sharing: Users were led to believe that their sensitive health information was protected, but evidence suggests that this data was shared with third parties for advertising purposes, thereby breaching the trust of its customer base.
• - Rapid Prescription Billing: Consumers found themselves billed for services nearly instantaneously upon submitting forms without having the promised consultations, raising concerns that Hims mismanaged its billing practices and customer consent procedures.

The implications of these allegations have been severe, as reflected in the company's market performance. After the FTС's complaint became public on July 29, 2026, Hims's stock took a sharp decline—losing over 14% in a single day and translating to a staggering loss of approximately $970 million in market value. This rapid downturn has amplified investor fears regarding the viability and strategy of Hims moving forward.

Call to Action for Affected Investors

As a result of these circumstances, Hagens Berman, the law firm representing investors, has encouraged individuals who suffered financial losses due to these developments to come forward. They are actively seeking to gather evidence and testimonies that will support the class action case.

Current Timeline: The class period for affected investors spans from August 4, 2025, to July 29, 2026. Those interested in participating should be aware that the deadline for filing the lead plaintiff application is set for November 2, 2026.

Investors with precise details regarding their losses or general assistance with the ongoing investigation are urged to reach out. Whistleblowers with non-public information may also play a crucial role in shedding light on Hims’s internal practices, with incentivized programs available that can reward them under SEC guidelines.

Conclusion

With the legal landscape shifting rapidly for Hims & Hers Health, many are left anxiously watching the litigation unfold. The results of this class action could set precedence for transparency and accountability in the healthcare technology industry, reshaping how companies handle consumer information and manage their marketing claims. As the investigation continues, the stakes for investors and consumers alike remain high.